Welcome and Introduction (5 min)
Immune Checkpoint Inhibitor in Advanced TNBC (25 min)
Immune Checkpoint Inhibitor in Early-Stage TNBC (25 min)
Managing Toxicities of Immunotherapies (15 min)
Panel Discussion and Audience Question and Answer Session (15 min)
Final Thoughts and Wrap-up (5 min)
Heather McArthur, MD
Department of Medicine
Medical Director, Breast Oncology
Samuel Oschin Comprehensive Cancer Center
Cedars-Sinai Medical Center
Los Angeles, California
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate immunotherapies into the treatment of patients with triple-negative breast cancer.
This program is intended for physicians and other healthcare providers who care for patients with triple-negative breast cancer.
Upon completion of this activity, participants should be able to:
- Evaluate available data on the use of immune checkpoint inhibitor-based combinations as part of neoadjuvant/adjuvant therapy for early stage breast cancer
- Plan first-line treatment with immune checkpoint inhibitor–based therapy for individual patients with locally advanced or metastatic triple-negative breast cancer
- Apply clinical evidence and expert recommendations on immune checkpoint inhibitors for patients with progressive triple-negative breast cancer after 1 or more previous lines of therapy
- Recommend ongoing clinical trials assessing new therapeutic approaches for appropriate patients with triple-negative breast cancer
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.